19.07.2016, 14:34

Johnson & Johnson today announced sales of $18.5 billion for the second quarter of 2016

OREANDA-NEWS. Johnson & Johnson (NYSE: JNJ) today announced sales of $18.5 billion for the second quarter of 2016, an increase of 3.9% as compared to the second quarter of 2015. Operational sales results increased 5.3% and the negative impact of currency was 1.4%. Domestic sales increased 7.4%. International sales increased 0.4%, reflecting operational growth of 3.1% and a negative currency impact of 2.7%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 7.9%, domestic sales increased 8.8% and international sales increased 6.9%.^* Operations in Venezuela negatively impacted worldwide operational sales growth by 30 basis points, and international sales growth by 70 basis points.

Net earnings and diluted earnings per share for the second quarter of 2016 were $4.0 billion and $1.43, respectively. Second quarter 2016 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a charge for after-tax special items of approximately $0.7 billion. Second quarter 2015 net earnings included after-tax intangible amortization expense of approximately $0.2 billion and a charge for after-tax special items of approximately $0.1 billion. Excluding after-tax intangible amortization expense and special items, adjusted net earnings for the current quarter were $4.9 billion and adjusted diluted earnings per share were $1.74, representing increases of 1.1% and 1.8%, respectively, as compared to the same period in 2015.^* On an operational basis, adjusted diluted earnings per share also increased 1.8%.^*A reconciliation of non-GAAP financial measures is included as an accompanying schedule.

"We continue to see good momentum through the first half of 2016, delivering solid results in the second quarter, supported by strong underlying growth across our enterprise," said Alex Gorsky, Chairman and Chief Executive Officer. "We saw notable strength in our Pharmaceuticals business due to the continued success of new products, and also achieved significant clinical milestones, advancing our robust pipeline. In our Consumer business, we are executing strategic portfolio decisions to expand our market leadership in key segments, and in Medical Devices, we are continuing to accelerate our growth driven by new product launches and transforming our commercial models."

Mr. Gorsky continued, "I am proud of our dedicated and talented employees whose commitment to advancing health and well-being for patients and consumers around the world is fueling our growth."

The Company increased its sales guidance for the full-year 2016 to $71.5 billion to $72.2 billion. Additionally, the Company increased its adjusted earnings guidance for full-year 2016 to $6.63 - $6.73 per share.*

Worldwide Consumer sales of $3.4 billion for the second quarter 2016 represented a decrease of 1.8% versus the prior year, consisting of an operational increase of 1.5% and a negative impact from currency of 3.3%. Domestic sales increased 2.1%; international sales decreased 4.4%, which reflected an operational increase of 1.0% and a negative currency impact of 5.4%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 3.9%, domestic sales increased 6.8% and international sales increased 2.0%^*. Operations in Venezuela negatively impacted worldwide Consumer operational sales growth by 120 basis points, and international sales growth by 200 basis points.

Primary contributors to Consumer operational sales results were NEUTROGENA^® and AVEENO^®skin care products; over-the-counter products, including TYLENOL^® and MOTRIN^® analgesics, digestive health products and international anti-smoking aids; and LISTERINE^® oral care products.

During the quarter, the acquisitions of NeoStrata Company, Inc., a global leader in dermocosmetics, and the HIPOGL?S^® diaper rash cream brand in Brazil were completed. In addition, subsequent to the quarter, the acquisition of Vogue International LLC, a privately-held company focused on the marketing, development and distribution of salon-influenced and nature inspired hair care and other personal care products, was completed for $3.3 billion in cash.

Worldwide Pharmaceutical sales of $8.7 billion for the second quarter 2016 represented an increase of 8.9% versus the prior year with an operational increase of 9.7% and a negative impact from currency of 0.8%. Domestic sales increased 13.2%; international sales increased 3.1%, which reflected an operational increase of 4.9% and a negative currency impact of 1.8%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 12.8%, domestic sales increased 13.9% and international sales increased 11.2%.^*

Worldwide operational sales growth was driven by new products and the strength of core products. Strong growth in new products include IMBRUVICA^® (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer; XARELTO^® (rivaroxaban), an oral anticoagulant; DARZALEX^®(daratumumab), for the treatment of patients with multiple myeloma; INVOKANA^®/INVOKAMET^®(canagliflozin), for the treatment of adults with type 2 diabetes; and ZYTIGA^® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer. New product sales growth was negatively impacted by lower sales of OLYSIO^®/SOVRIAD^®(simeprevir) due to competitive entrants.

Additional contributors to operational sales growth include STELARA^® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; SIMPONI^®/SIMPONI ARIA^® (golimumab) and REMICADE^® (infliximab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; and INVEGA^®SUSTENNA^®/XEPLION^®/TRINZA^® (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults.

During the quarter, the U.S. Food and Drug Administration (FDA) approved an additional indication for INVOKAMET^® (canagliflozin/metformin HCl) for first-line treatment of adults with type 2 diabetes and an expanded label for IMBRUVICA^® (ibrutinib) to include overall survival and combination data in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The European Commission (EC) granted conditional approval to DARZALEX^® (daratumumab) for monotherapy of adult patients with relapsed and refractory multiple myeloma and also approved IMBRUVICA^® (ibrutinib) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia, TREVICTA^® (paliperidone palmitate a 3 monthly injection) for the maintenance treatment of schizophrenia in adult patients, and SIMPONI^® (golimumab) for the treatment of polyarticular juvenile idiopathic arthritis.

In addition, the divestiture of the company's controlled substance raw material and active pharmaceutical ingredient business to SK Capital Partners, a private equity company, was completed.

Worldwide Medical Devices sales of $6.4 billion for the second quarter 2016 represented an increase of 0.8% versus the prior year consisting of an operational increase of 1.8% and a negative currency impact of 1.0%. Domestic sales increased 1.0%; international sales increased 0.6%, which reflected an operational increase of 2.6% and a negative currency impact of 2.0%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 3.9%, domestic sales increased 1.9% and international sales increased 5.8%.^* Operations in Venezuela negatively impacted worldwide operational sales growth by 30 basis points, and international sales growth by 50 basis points.

Primary contributors to operational sales growth were endocutters, energy and biosurgical products in the Advanced Surgery business; electrophysiology products in the Cardiovascular business; joint reconstruction and U.S. trauma products in the Orthopaedics business; and ACUVUE^® contact lenses in the Vision Care business.

During the quarter, the acquisition of privately-held BioMedical Enterprises, Inc., a leading manufacturer of Nitinol orthopaedic implants for small bone fixation, was completed.

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SECOND QUARTER						SIX MONTHS
			Percent Change						Percent Change
	2016	2015	Total		Operations	Currency	2016	2015	Total		Operations	Currency
Sales to customers by
segment of business

Consumer
U.S.	$ 1,384	1,355	2.1	%	2.1	-	$ 2,742	2,714	1.0	%	1.0	-
International	2,035	2,128	(4.4)		1.0	(5.4)	3,872	4,159	(6.9)		0.4	(7.3)
	3,419	3,483	(1.8)		1.5	(3.3)	6,614	6,873	(3.8)		0.6	(4.4)

Pharmaceutical
U.S.	5,144	4,543	13.2		13.2	-	10,081	8,914	13.1		13.1	-
International	3,510	3,403	3.1		4.9	(1.8)	6,751	6,758	(0.1)		3.8	(3.9)
	8,654	7,946	8.9		9.7	(0.8)	16,832	15,672	7.4		9.1	(1.7)

Medical Devices
U.S.	3,044	3,013	1.0		1.0	-	6,070	5,975	1.6		1.6	-
International	3,365	3,345	0.6		2.6	(2.0)	6,448	6,641	(2.9)		0.8	(3.7)
	6,409	6,358	0.8		1.8	(1.0)	12,518	12,616	(0.8)		1.2	(2.0)

U.S.	9,572	8,911	7.4		7.4	-	18,893	17,603	7.3		7.3	-
International	8,910	8,876	0.4		3.1	(2.7)	17,071	17,558	(2.8)		1.8	(4.6)
Worldwide	$ 18,482	17,787	3.9	%	5.3	(1.4)	$ 35,964	35,161	2.3	%	4.6	(2.3)

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SECOND QUARTER						SIX MONTHS
			Percent Change						Percent Change
	2016	2015	Total		Operations	Currency	2016	2015	Total		Operations	Currency
Sales to customers by
geographic area

U.S.	$ 9,572	8,911	7.4	%	7.4	-	$ 18,893	17,603	7.3	%	7.3	-

Europe	4,090	4,151	(1.5)		(0.6)	(0.9)	7,937	8,191	(3.1)		(0.6)	(2.5)
Western Hemisphere excluding U.S.	1,542	1,501	2.7		15.4	(12.7)	2,873	3,140	(8.5)		7.1	(15.6)
Asia-Pacific, Africa	3,278	3,224	1.7		2.1	(0.4)	6,261	6,227	0.5		2.5	(2.0)
International	8,910	8,876	0.4		3.1	(2.7)	17,071	17,558	(2.8)		1.8	(4.6)

Worldwide	$ 18,482	17,787	3.9	%	5.3	(1.4)	$ 35,964	35,161	2.3	%	4.6	(2.3)

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	SECOND QUARTER

	2016			2015			Percent
			Percent			Percent	Increase
	Amount		to Sales	Amount		to Sales	(Decrease)
Sales to customers	$ 18,482		100.0	$ 17,787		100.0	3.9
Cost of products sold	5,336		28.9	5,357		30.1	(0.4)
Selling, marketing and administrative expenses	5,176		28.0	5,384		30.3	(3.9)
Research and development expense	2,264		12.2	2,129		12.0	6.3
In-process research and development	29		0.2	-		-
Interest (income) expense, net	102		0.6	107		0.6
Other (income) expense, net	557		3.0	(931)		(5.3)
Restructuring	114		0.6	-		-
Earnings before provision for taxes on income	4,904		26.5	5,741		32.3	(14.6)
Provision for taxes on income	907		4.9	1,225		6.9	(26.0)
Net earnings	$ 3,997		21.6	$ 4,516		25.4	(11.5)

Net earnings per share (Diluted)	$ 1.43			$ 1.61			(11.2)

Average shares outstanding (Diluted)	2,794.2			2,812.0

Effective tax rate	18.5	%		21.3	%

Adjusted earnings before provision for taxes and net earnings ⁽¹⁾
Earnings before provision for taxes on income	$ 6,024		32.6	$ 6,248		35.1	(3.6)
Net earnings	$ 4,866		26.3	$ 4,812		27.1	1.1
Net earnings per share (Diluted)	$ 1.74			$ 1.71			1.8
Effective tax rate	19.2	%		23.0	%

⁽¹⁾See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	SIX MONTHS

	2016			2015			Percent
			Percent			Percent	Increase
	Amount		to Sales	Amount		to Sales	(Decrease)
Sales to customers	$ 35,964		100.0	$ 35,161		100.0	2.3
Cost of products sold	10,665		29.6	10,639		30.2	0.2
Selling, marketing and administrative expenses	9,864		27.4	10,231		29.1	(3.6)
Research and development expense	4,277		11.9	4,028		11.5	6.2
In-process research and development	29		0.1	-		-
Interest (income) expense, net	179		0.5	226		0.6
Other (income) expense, net	518		1.4	(1,279)		(3.6)
Restructuring	234		0.7	-		-
Earnings before provision for taxes on income	10,198		28.4	11,316		32.2	(9.9)
Provision for taxes on income	1,744		4.9	2,480		7.1	(29.7)
Net earnings	$ 8,454		23.5	$ 8,836		25.1	(4.3)

Net earnings per share (Diluted)	$ 3.02			$ 3.13			(3.5)

Average shares outstanding (Diluted)	2,800.9			2,821.0

Effective tax rate	17.1	%		21.9	%

Adjusted earnings before provision for taxes and net earnings ⁽¹⁾
Earnings before provision for taxes on income	$ 11,825		32.9	$ 11,878		33.8	(0.4)
Net earnings	$ 9,720		27.0	$ 9,230		26.3	5.3
Net earnings per share (Diluted)	$ 3.47			$ 3.27			6.1
Effective tax rate	17.8	%		22.3	%

⁽¹⁾See Reconciliation of Non-GAAP Financial Measures.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	Second Quarter		% Incr. /		Six Months YTD		% Incr. /
(Dollars in Millions Except Per Share Data)	2016	2015	(Decr.)		2016	2015	(Decr.)

Earnings before provision for taxes on income - as reported	$ 4,904	5,741	(14.6)	%	$ 10,198	11,316	(9.9)	%

Intangible asset amortization expense	326	318			608	630

Restructuring/Other ⁽¹⁾	141	-			278	-

Litigation expense/(gain), net	600	134			666	(268)

DePuy ASR™ Hip program	-	9			-	148

In-process research and development	29	-			29	-

Other	24	46			46	52

Earnings before provision for taxes on income - as adjusted	$ 6,024	6,248	(3.6)	%	$ 11,825	11,878	(0.4)	%

Net Earnings - as reported	$ 3,997	4,516	(11.5)	%	$ 8,454	8,836	(4.3)	%

Intangible asset amortization expense	238	230			443	456

Restructuring/Other	97	-			217	-

Litigation expense/(gain), net	493	23			549	(230)

DePuy ASR™ Hip program	-	8			-	130

In-process research and development	23	-			23	-

Other	18	35			34	38

Net Earnings - as adjusted	$ 4,866	4,812	1.1	%	$ 9,720	9,230	5.3	%

Diluted Net Earnings per share - as reported	$ 1.43	1.61	(11.2)	%	$ 3.02	3.13	(3.5)	%

Intangible asset amortization expense	0.08	0.08			0.16	0.16

Restructuring/Other	0.03	-			0.08	-

Litigation expense/(gain), net	0.18	0.01			0.19	(0.08)

DePuy ASR™ Hip program	-	-			-	0.05

In-process research and development	0.01	-			0.01	-

Other	0.01	0.01			0.01	0.01

Diluted Net Earnings per share - as adjusted	$ 1.74	1.71	1.8	%	$ 3.47	3.27	6.1	%

Operational Diluted Net Earnings per share - as adjusted at 2014 foreign currency exchange rates		1.90				3.59

Impact of currency at 2015 foreign currency exchange rates	$ -	(0.19)			$ 0.04	(0.32)

Operational Diluted Net Earnings per share - as adjusted at 2015 foreign currency exchange rates	$ 1.74	1.71	1.8	%	$ 3.51	3.27	7.3	%


⁽¹⁾Includes $7M recorded in cost of products sold and $20M recorded in other (income) expense for the second quarter.
Includes $24M recorded in cost of products sold and $20M recorded in other (income) expense for six months YTD.

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Operational Sales Growth Excluding Acquisitions, Divestitures and Hepatitis C Sales ⁽¹⁾
SECOND QUARTER 2016 ACTUAL vs. 2015 ACTUAL


Segments

	Consumer	Pharmaceutical	Medical Devices	Total
	Operational % ⁽²⁾
WW As Reported:	1.5%	9.7%	1.8%	5.3%
U.S.	2.1%	13.2%	1.0%	7.4%
International	1.0%	4.9%	2.6%	3.1%

Wound Care/Other
*SPLENDA^®*	2.5			0.5
U.S.	4.9			0.7
International	1.0			0.2

Cardiovascular
*Cordis*			2.3	0.8
U.S.			1.1	0.4
International			3.5	1.3

All Other Acquisitions and Divestitures	(0.1)	(0.1)	(0.2)	(0.1)
U.S.	(0.2)	(0.1)	(0.2)	(0.1)
International	0.0	0.0	(0.3)	(0.1)

WW Ops excluding Acquisitions and Divestitures	3.9%	9.6%	3.9%	6.5%
U.S.	6.8%	13.1%	1.9%	8.4%
International	2.0%	4.9%	5.8%	4.5%

Hepatitis C		3.2		1.4
U.S.		0.8		0.4
International		6.3		2.4

WW Ops excluding Hepatitis C only		12.9%		6.7%
U.S.		14.0%		7.8%
International		11.2%		5.5%

WW Ops excluding Acquisitions, Divestitures and Hepatitis C	3.9%	12.8%	3.9%	7.9%
U.S.	6.8%	13.9%	1.9%	8.8%
International	2.0%	11.2%	5.8%	6.9%


⁽¹⁾Hepatitis C products include OLYSIO ^®/SOVRIAD ^®and INCIVO ^®
⁽²⁾Operational growth excludes the effect of translational currency

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure

Operational Sales Growth Excluding Acquisitions, Divestitures and Hepatitis C Sales ⁽¹⁾
SIX MONTHS 2016 ACTUAL vs. 2015 ACTUAL


Segments

	Consumer	Pharmaceutical	Medical Devices	Total
	Operational % ⁽²⁾
WW As Reported:	0.6%	9.1%	1.2%	4.6%
U.S.	1.0%	13.1%	1.6%	7.3%
International	0.4%	3.8%	0.8%	1.8%

Wound Care/Other
*SPLENDA^®*	2.3			0.4
U.S.	4.5			0.7
International	0.8			0.2

Cardiovascular
*Cordis*			2.3	0.9
U.S.			1.1	0.4
International			3.5	1.4

All Other Acquisitions and Divestitures	0.0	0.2	(0.1)	0.1
U.S.	(0.1)	0.4	(0.1)	0.2
International	0.1	0.0	0.0	0.0

WW Ops excluding Acquisitions and Divestitures	2.9%	9.3%	3.4%	6.0%
U.S.	5.4%	13.5%	2.6%	8.6%
International	1.3%	3.8%	4.3%	3.4%


Hepatitis C		3.2		1.4
U.S.		1.5		0.7
International		5.4		2.0

WW Ops excluding Hepatitis C only		12.3%		6.0%
U.S.		14.6%		8.0%
International		9.2%		3.8%

WW Ops excluding Acquisitions, Divestitures, and Hepatitis C	2.9%	12.5%	3.4%	7.4%
U.S.	5.4%	15.0%	2.6%	9.3%
International	1.3%	9.2%	4.3%	5.4%

⁽¹⁾Hepatitis C products include OLYSIO ^®/SOVRIAD ^®and INCIVO ^®
⁽²⁾Operational growth excludes the effect of translational currency

		REPORTED SALES vs. PRIOR PERIOD ($MM)
	SECOND QUARTER						SIX MONTHS
				% Change						% Change
		2016	2015	Reported	Operational ⁽¹⁾	Currency		2016	2015	Reported	Operational ⁽¹⁾	Currency
CONSUMER SEGMENT ⁽²⁾
BABY CARE
US		$ 102	104	-1.9%	-1.9%	-		$ 197	215	-8.4%	-8.4%	-
Intl		398	439	-9.3%	-2.2%	-7.1%		754	839	-10.1%	-1.1%	-9.0%
WW		500	543	-7.9%	-2.1%	-5.8%		951	1,054	-9.8%	-2.6%	-7.2%
ORAL CARE
US		159	147	8.2%	8.2%	-		329	305	7.9%	7.9%	-
Intl		244	244	0.0%	5.6%	-5.6%		459	489	-6.1%	1.3%	-7.4%
WW		403	391	3.1%	6.6%	-3.5%		788	794	-0.8%	3.8%	-4.6%
OTC
US		389	366	6.3%	6.3%	-		850	771	10.2%	10.2%	-
Intl		619	608	1.8%	6.1%	-4.3%		1,177	1,196	-1.6%	4.5%	-6.1%
WW		1,008	974	3.5%	6.2%	-2.7%		2,027	1,967	3.1%	6.8%	-3.7%
SKIN CARE
US		555	491	13.0%	13.0%	-		1,043	983	6.1%	6.1%	-
Intl		398	403	-1.2%	3.5%	-4.7%		772	814	-5.2%	1.3%	-6.5%
WW		953	894	6.6%	8.7%	-2.1%		1,815	1,797	1.0%	3.9%	-2.9%
WOMEN'S HEALTH
US		7	7	0.0%	0.0%	-		13	13	0.0%	0.0%	-
Intl		276	313	-11.8%	-4.8%	-7.0%		521	594	-12.3%	-3.0%	-9.3%
WW		283	320	-11.6%	-4.8%	-6.8%		534	607	-12.0%	-2.9%	-9.1%
WOUND CARE / OTHER
US		172	240	-28.3%	-28.3%	-		310	427	-27.4%	-27.4%	-
Intl		100	121	-17.4%	-14.2%	-3.2%		189	227	-16.7%	-11.4%	-5.3%
WW		272	361	-24.7%	-23.6%	-1.1%		499	654	-23.7%	-21.9%	-1.8%

TOTAL CONSUMER
US		1,384	1,355	2.1%	2.1%	-		2,742	2,714	1.0%	1.0%	-
Intl		2,035	2,128	-4.4%	1.0%	-5.4%		3,872	4,159	-6.9%	0.4%	-7.3%
WW		$ 3,419	3,483	-1.8%	1.5%	-3.3%		$ 6,614	6,873	-3.8%	0.6%	-4.4%


		REPORTED SALES vs. PRIOR PERIOD ($MM)
	SECOND QUARTER						SIX MONTHS
				% Change						% Change
		2016	2015	Reported	Operational ⁽¹⁾	Currency		2016	2015	Reported	Operational ⁽¹⁾	Currency
PHARMACEUTICAL SEGMENT ⁽²⁾
IMMUNOLOGY
US		$ 2,224	1,876	18.6%	18.6%	-		$ 4,395	3,631	21.0%	21.0%	-
Intl		814	678	20.1%	23.0%	-2.9%		1,553	1,386	12.0%	17.7%	-5.7%
WW		3,038	2,554	19.0%	19.8%	-0.8%		5,948	5,017	18.6%	20.2%	-1.6%
REMICADE
US		1,236	1,088	13.6%	13.6%	-		2,447	2,143	14.2%	14.2%	-
US Exports ⁽³⁾		185	241	-23.2%	-23.2%	-		418	422	-0.9%	-0.9%	-
Intl		359	339	5.9%	11.1%	-5.2%		694	703	-1.3%	6.2%	-7.5%
WW		1,780	1,668	6.7%	7.7%	-1.0%		3,559	3,268	8.9%	10.5%	-1.6%
SIMPONI / SIMPONI ARIA
US		244	172	41.9%	41.9%	-		460	327	40.7%	40.7%	-
Intl		204	136	50.0%	49.7%	0.3%		378	281	34.5%	38.3%	-3.8%
WW		448	308	45.5%	45.4%	0.1%		838	608	37.8%	39.5%	-1.7%
STELARA
US		559	375	49.1%	49.1%	-		1,070	739	44.8%	44.8%	-
Intl		245	195	25.6%	26.4%	-0.8%		469	380	23.4%	26.8%	-3.4%
WW		804	570	41.1%	41.4%	-0.3%		1,539	1,119	37.5%	38.7%	-1.2%
OTHER IMMUNOLOGY
US		-	-	-	-	-		-	-	-	-	-
Intl		6	8	-25.0%	-15.2%	-9.8%		12	22	-45.5%	-36.4%	-9.1%
WW		6	8	-25.0%	-15.2%	-9.8%		12	22	-45.5%	-36.4%	-9.1%
INFECTIOUS DISEASES
US		362	381	-5.0%	-5.0%	-		720	793	-9.2%	-9.2%	-
Intl		467	651	-28.3%	-27.3%	-1.0%		885	1,214	-27.1%	-24.8%	-2.3%
WW		829	1,032	-19.7%	-19.1%	-0.6%		1,605	2,007	-20.0%	-18.6%	-1.4%
EDURANT
US		14	9	55.6%	55.6%	-		25	18	38.9%	38.9%	-
Intl		126	92	37.0%	35.1%	1.9%		234	174	34.5%	35.2%	-0.7%
WW		140	101	38.6%	36.9%	1.7%		259	192	34.9%	35.6%	-0.7%
OLYSIO / SOVRIAD
US		21	50	-58.0%	-58.0%	-		37	148	-75.0%	-75.0%	-
Intl		22	214	-89.7%	-89.4%	-0.3%		38	350	-89.1%	-88.5%	-0.6%
WW		43	264	-83.7%	-83.5%	-0.2%		75	498	-84.9%	-84.5%	-0.4%
PREZISTA / PREZCOBIX / REZOLSTA
US		273	258	5.8%	5.8%	-		550	492	11.8%	11.8%	-
Intl		186	190	-2.1%	-0.6%	-1.5%		361	383	-5.7%	-2.6%	-3.1%
WW		459	448	2.5%	3.1%	-0.6%		911	875	4.1%	5.5%	-1.4%
OTHER INFECTIOUS DISEASES
US		54	64	-15.6%	-15.6%	-		108	135	-20.0%	-20.0%	-
Intl		133	155	-14.2%	-11.2%	-3.0%		252	307	-17.9%	-13.9%	-4.0%
WW		187	219	-14.6%	-12.5%	-2.1%		360	442	-18.6%	-15.8%	-2.8%
See footnotes at end of schedule
		REPORTED SALES vs. PRIOR PERIOD ($MM)
	SECOND QUARTER						SIX MONTHS
				% Change						% Change
		2016	2015	Reported	Operational ⁽¹⁾	Currency		2016	2015	Reported	Operational ⁽¹⁾	Currency
NEUROSCIENCE
US		695	693	0.3%	0.3%	-		1,375	1,443	-4.7%	-4.7%	-
Intl		907	871	4.1%	4.7%	-0.6%		1,776	1,739	2.1%	5.1%	-3.0%
WW		1,602	1,564	2.4%	2.8%	-0.4%		3,151	3,182	-1.0%	0.6%	-1.6%
CONCERTA / METHYLPHENIDATE
US		129	102	26.5%	26.5%	-		263	228	15.4%	15.4%	-
Intl		109	104	4.8%	8.4%	-3.6%		206	202	2.0%	7.4%	-5.4%
WW		238	206	15.5%	17.3%	-1.8%		469	430	9.1%	11.7%	-2.6%
INVEGA / PALIPERIDONE
US		18	105	-82.9%	-82.9%	-		42	199	-78.9%	-78.9%	-
Intl		64	61	4.9%	3.4%	1.5%		126	122	3.3%	4.4%	-1.1%
WW		82	166	-50.6%	-51.2%	0.6%		168	321	-47.7%	-47.3%	-0.4%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA
US		339	253	34.0%	34.0%	-		644	481	33.9%	33.9%	-
Intl		221	183	20.8%	21.2%	-0.4%		429	366	17.2%	20.2%	-3.0%
WW		560	436	28.4%	28.6%	-0.2%		1,073	847	26.7%	28.0%	-1.3%
RISPERDAL CONSTA
US		100	99	1.0%	1.0%	-		195	203	-3.9%	-3.9%	-
Intl		130	148	-12.2%	-11.9%	-0.3%		266	298	-10.7%	-8.4%	-2.3%
WW		230	247	-6.9%	-6.7%	-0.2%		461	501	-8.0%	-6.6%	-1.4%
OTHER NEUROSCIENCE
US		109	134	-18.7%	-18.7%	-		231	332	-30.4%	-30.4%	-
Intl		383	375	2.1%	2.6%	-0.5%		749	751	-0.3%	2.6%	-2.9%
WW		492	509	-3.3%	-3.0%	-0.3%		980	1,083	-9.5%	-7.5%	-2.0%
ONCOLOGY
US		569	362	57.2%	57.2%	-		1,118	696	60.6%	60.6%	-
Intl		905	782	15.7%	17.1%	-1.4%		1,710	1,556	9.9%	13.5%	-3.6%
WW		1,474	1,144	28.8%	29.8%	-1.0%		2,828	2,252	25.6%	28.1%	-2.5%
IMBRUVICA
US		144	89	61.8%	61.8%	-		276	155	78.1%	78.1%	-
Intl		151	65	*	*	**		280	115	*	*	**
WW		295	154	91.6%	93.1%	-1.5%		556	270	*	*	**
VELCADE
US		-	-	-	-	-		-	-	-	-	-
Intl		342	344	-0.6%	1.4%	-2.0%		646	683	-5.4%	-2.0%	-3.4%
WW		342	344	-0.6%	1.4%	-2.0%		646	683	-5.4%	-2.0%	-3.4%
ZYTIGA
US		286	255	12.2%	12.2%	-		558	508	9.8%	9.8%	-
Intl		315	291	8.2%	8.4%	-0.2%		601	594	1.2%	4.1%	-2.9%
WW		601	546	10.1%	10.2%	-0.1%		1,159	1,102	5.2%	6.8%	-1.6%
OTHER ONCOLOGY
US		139	18	*	*	-		284	33	*	*	-
Intl		97	82	18.3%	20.1%	-1.8%		183	164	11.6%	15.6%	-4.0%
WW		236	100	*	*	**		467	197	*	*	**
CARDIOVASCULAR / METABOLISM / OTHER
US		1,294	1,231	5.1%	5.1%	-		2,473	2,351	5.2%	5.2%	-
Intl		417	421	-1.0%	3.2%	-4.2%		827	863	-4.2%	1.4%	-5.6%
WW		1,711	1,652	3.6%	4.7%	-1.1%		3,300	3,214	2.7%	4.2%	-1.5%
XARELTO
US		594	472	25.8%	25.8%	-		1,161	913	27.2%	27.2%	-
Intl		-	-	-	-	-		-	-	-	-	-
WW		594	472	25.8%	25.8%	-		1,161	913	27.2%	27.2%	-
INVOKANA / INVOKAMET
US		348	302	15.2%	15.2%	-		645	568	13.6%	13.6%	-
Intl		35	16	*	*	**		63	28	*	*	**
WW		383	318	20.4%	21.0%	-0.6%		708	596	18.8%	19.5%	-0.7%
PROCRIT / EPREX
US		230	179	28.5%	28.5%	-		413	342	20.8%	20.8%	-
Intl		92	97	-5.2%	-2.9%	-2.3%		183	203	-9.9%	-5.9%	-4.0%
WW		322	276	16.7%	17.5%	-0.8%		596	545	9.4%	10.9%	-1.5%
OTHER
US		122	278	-56.1%	-56.1%	-		254	528	-51.9%	-51.9%	-
Intl		290	308	-5.8%	-1.4%	-4.4%		581	632	-8.1%	-2.5%	-5.6%
WW		412	586	-29.7%	-27.4%	-2.3%		835	1,160	-28.0%	-25.0%	-3.0%

TOTAL PHARMACEUTICAL
US		5,144	4,543	13.2%	13.2%	-		10,081	8,914	13.1%	13.1%	-
Intl		3,510	3,403	3.1%	4.9%	-1.8%		6,751	6,758	-0.1%	3.8%	-3.9%
WW		$ 8,654	7,946	8.9%	9.7%	-0.8%		$ 16,832	15,672	7.4%	9.1%	-1.7%

See footnotes at end of schedule
		REPORTED SALES vs. PRIOR PERIOD ($MM)
	SECOND QUARTER						SIX MONTHS
				% Change						% Change
		2016	2015	Reported	Operational ⁽¹⁾	Currency		2016	2015	Reported	Operational ⁽¹⁾	Currency
MEDICAL DEVICES SEGMENT ^{(2) (4)}
CARDIOVASCULAR
US		$ 235	235	0.0%	0.0%	-		$ 466	463	0.6%	0.6%	-
Intl		235	309	-23.9%	-23.8%	-0.1%		447	610	-26.7%	-25.0%	-1.7%
WW		470	544	-13.6%	-13.6%	0.0%		913	1,073	-14.9%	-14.0%	-0.9%
DIABETES CARE
US		177	214	-17.3%	-17.3%	-		357	426	-16.2%	-16.2%	-
Intl		294	280	5.0%	7.0%	-2.0%		543	552	-1.6%	2.2%	-3.8%
WW		471	494	-4.7%	-3.5%	-1.2%		900	978	-8.0%	-5.8%	-2.2%
DIAGNOSTICS
US		-	-	-	-	-		-	-	-	-	-
Intl		31	16	93.8%	*	**		59	46	28.3%	47.8%	-19.5%
WW		31	16	93.8%	*	**		59	46	28.3%	47.8%	-19.5%
ORTHOPAEDICS
US		1,364	1,321	3.3%	3.3%	-		2,756	2,630	4.8%	4.8%	-
Intl		991	1,009	-1.8%	0.2%	-2.0%		1,940	2,028	-4.3%	-0.5%	-3.8%
WW		2,355	2,330	1.1%	2.0%	-0.9%		4,696	4,658	0.8%	2.4%	-1.6%
HIPS
US		197	193	2.1%	2.1%	-		400	383	4.4%	4.4%	-
Intl		152	143	6.3%	9.6%	-3.3%		291	286	1.7%	6.5%	-4.8%
WW		349	336	3.9%	5.3%	-1.4%		691	669	3.3%	5.3%	-2.0%
KNEES
US		229	222	3.2%	3.2%	-		473	448	5.6%	5.6%	-
Intl		156	150	4.0%	6.7%	-2.7%		301	300	0.3%	4.4%	-4.1%
WW		385	372	3.5%	4.6%	-1.1%		774	748	3.5%	5.1%	-1.6%
TRAUMA
US		381	351	8.5%	8.5%	-		762	715	6.6%	6.6%	-
Intl		255	270	-5.6%	-3.8%	-1.8%		516	562	-8.2%	-4.4%	-3.8%
WW		636	621	2.4%	3.2%	-0.8%		1,278	1,277	0.1%	1.8%	-1.7%
SPINE & OTHER
US		557	555	0.4%	0.4%	-		1,121	1,084	3.4%	3.4%	-
Intl		428	446	-4.0%	-2.5%	-1.5%		832	880	-5.5%	-2.2%	-3.3%
WW		985	1,001	-1.6%	-0.9%	-0.7%		1,953	1,964	-0.6%	0.9%	-1.5%
SURGERY
US		1,020	1,000	2.0%	2.0%	-		2,001	1,960	2.1%	2.1%	-
Intl		1,377	1,328	3.7%	6.4%	-2.7%		2,624	2,624	0.0%	4.4%	-4.4%
WW		2,397	2,328	3.0%	4.6%	-1.6%		4,625	4,584	0.9%	3.4%	-2.5%
ADVANCED
US		389	360	8.1%	8.1%	-		741	689	7.5%	7.5%	-
Intl		520	480	8.3%	11.0%	-2.7%		984	921	6.8%	11.3%	-4.5%
WW		909	840	8.2%	9.7%	-1.5%		1,725	1,610	7.1%	9.7%	-2.6%
GENERAL
US		421	423	-0.5%	-0.5%	-		840	845	-0.6%	-0.6%	-
Intl		706	696	1.4%	3.9%	-2.5%		1,357	1,407	-3.6%	0.5%	-4.1%
WW		1,127	1,119	0.7%	2.3%	-1.6%		2,197	2,252	-2.4%	0.2%	-2.6%
SPECIALTY
US		210	217	-3.2%	-3.2%	-		420	426	-1.4%	-1.4%	-
Intl		151	152	-0.7%	2.8%	-3.5%		283	296	-4.4%	1.0%	-5.4%
WW		361	369	-2.2%	-0.7%	-1.5%		703	722	-2.6%	-0.4%	-2.2%
VISION CARE
US		248	243	2.1%	2.1%	-		490	496	-1.2%	-1.2%	-
Intl		437	403	8.4%	8.1%	0.3%		835	781	6.9%	8.9%	-2.0%
WW		685	646	6.0%	5.8%	0.2%		1,325	1,277	3.8%	5.0%	-1.2%

TOTAL MEDICAL DEVICES
US		3,044	3,013	1.0%	1.0%	-		6,070	5,975	1.6%	1.6%	-
Intl		3,365	3,345	0.6%	2.6%	-2.0%		6,448	6,641	-2.9%	0.8%	-3.7%
WW		$ 6,409	6,358	0.8%	1.8%	-1.0%		$ 12,518	12,616	-0.8%	1.2%	-2.0%

* Percentage greater than 100%
** Not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Reported as U.S. sales
(4) Prior year amounts have been reclassified to conform to current year product disclosure

Johnson & Johnson today announced sales of $18.5 billion for the second quarter of 2016

Комментарии

НОВОСТИ ПАРТНЁРОВ

Latest news in section